Products Categories
CAS No.: | 21416-67-1 |
---|---|
Name: | 4,4'-propylenebis(piperazine-2,6-dione) |
Article Data: | 1 |
Molecular Structure: | |
Formula: | C11H16 N4 O4 |
Molecular Weight: | 268.272 |
Synonyms: | 2,6-Piperazinedione,4,4'-propylenedi- (8CI);4,4'-Propylenebis(2,6-piperazinedione);4,4'-Propylenedi(2,6-piperazinedione);ICI 59118;ICRF 159;NSC 129943;Razoxane;Razoxin;Tepirone;Troxozone;83713-23-9; |
EINECS: | 244-379-2 |
Density: | 1.333g/cm3 |
Melting Point: | 193oC |
Boiling Point: | 531.5°Cat760mmHg |
Flash Point: | 275.3°C |
Solubility: | 3g/L(25 oC) |
Safety: | Suspected human carcinogen producing leukemia and skin tumors. Moderately toxic by intraperitoneal route. Human effects: normocytic anemia and thrombocytopenia. Human mutation data reported. When heated to decomposition it emits toxic fumes of NOx. |
PSA: | 98.82000 |
LogP: | -2.17490 |
What can I do for you?
Get Best Price
Razoxane with cas register number of 21416-67-1 is also named as Razoxanum ; Troxozone ; CCRIS 344 ; ICRF 159 ; ICRF-161 ; CHEBI:50231 ; CID88893 ; 4,4'-Propylenebis(piperazine-2,6-dione) ; Razoxanum ; 4,4'-(1-Methylethylene)bis(2,6-piperazinedione) ,and so on.
IUPAC Name: 4-[3-(3,5-Dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
CAS: 21416-67-1
Molecular Formula: C11H16N4O4
Molecular Weight: 268.26914
Molecular structure:
EINECS: 244-379-2
ACD/LogD (pH 5.5): -0.38
ACD/LogD (pH 7.4): -0.37
ACD/BCF (pH 5.5): 1
ACD/BCF (pH 7.4): 1
ACD/KOC (pH 5.5): 14.87
ACD/KOC (pH 7.4): 14.91
H bond acceptors: 8
H bond donors: 2
Freely Rotating Bonds: 3
Index of Refraction: 1.539
Molar Refractivity: 63.12 cm3
Molar Volume: 201.2 cm3
Polarizability: 25.02×10-24cm3
Surface Tension: 51.6 dyne/cm
Density: 1.333 g/cm3
Flash Point: 275.3 °C
Enthalpy of Vaporization: 80.71 kJ/mol
Boiling Point: 531.5 °C at 760 mmHg
Vapour Pressure: 2.22E-11 mmHg at 25°C
Razoxane (CAS No.21416-67-1) may be used as pharmaceutical material.
1. | dni-hmn:lym 20 mg/L | INNDDK Investigational New Drugs. The Journal of New Anticancer Agents. 1 (1983),283. | ||
2. | oms-hmn:lym 20 mg/L | INNDDK Investigational New Drugs. The Journal of New Anticancer Agents. 1 (1983),283. | ||
3. | mnt-mus-ipr 200 mg/kg | BJCAAI British Journal of Cancer. 52 (1985),725. | ||
4. | cyt-ham-orl 100 mg/kg | BJCAAI British Journal of Cancer. 52 (1985),725. | ||
5. | orl-man TDLo:693 mg/kg/77W-I:CAR | LANCAO Lancet. 2 (1981),1343. | ||
6. | orl-wmn TD:4650 mg/kg/2Y-C:CAR | LANCAO Lancet. 2 (1981),1343. | ||
7. | orl-wmn TDLo:3650 mg/kg/2Y-I:BLD | LANCAO Lancet. 2 (1987),1085. | ||
8. | unr-wmn TDLo:600 mg/kg/34W-I:BLD | BJDEAZ British Journal of Dermatology. 113 (1985),131. | ||
9. | unr-man TDLo:6467 mg/kg/6Y-I:BLD | BJDEAZ British Journal of Dermatology. 113 (1985),131. | ||
10. | ipr-mus LD50:500 mg/kg | CPBTAL Chemical and Pharmaceutical Bulletin. 29 (1981),1594. |
Suspected human carcinogen producing leukemia and skin tumors. Razoxane (CAS No.21416-67-1) is moderately toxic by intraperitoneal route. Human effects: normocytic anemia and thrombocytopenia. Human mutation data reported. When heated to decomposition it emits toxic fumes of NOx.